Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
INTRODUCTION
Acute myeloid leukemia (AML) accounts for one-fourth of acute leukemias in children, but it is responsible for more than half of the leukemia deaths in this patient population. 1 In contrast to the tremendous success in treating acute lymphoblastic leukemia over the last three decades, resulting in a >80% cure rate, improvements in AML therapy have been limited 1 
.
Resistance to cytarabine, the most active drug in the treatment of AML, is a major cause of treatment failure. 2, 3 Therefore, new therapies for children with AML are urgently needed.
Cytarabine is a prodrug that must be converted to a triphosphate derivative (ara-CTP) to exert its cytotoxic effects. 4 Cytarabine cytotoxicity is believed to result from a combination of DNA polymerase inhibition and incorporation of ara-CTP into DNA, resulting in chain termination and a blockade of DNA synthesis. 4 In addition, previous studies have documented the ability of cytarabine to trigger apoptosis in human leukemia cells. 4 Histone deacetylase (HDAC) inhibitors (HDACIs) promote histone acetylation and subsequent chromatin relaxation and uncoiling, which facilitates transcription of different genes, especially those involved in cellular differentiation. 5 HDACIs may also disrupt the function of HDACs in co-repressor complexes implicated in the differentiation blockade exhibited by certain forms of AML [e.g., t(8;21) AML and APL involving t(15;17)]. 6, 7 HDACI cytotoxicity is regulated by diverse mechanisms including activation of stress-related pathways or inactivation of cytoprotective pathways, up-regulation of death receptors, induction of p21 CIP1 , ceramide production, disruption of heat shock proteins, and induction of oxidative damage. 8 Further, emerging evidence suggests that HDACIs can directly induce DNA damage in leukemia cells. and to induce apoptosis in leukemia cells but not in normal cells at clinically achievable concentrations (100-150 μg/ml). [18] [19] [20] VPA is usually well tolerated in children and the extensive clinical experience with this drug makes it a very attractive agent for treating pediatric AML. In fact, preclinical and clinical studies have demonstrated additive-tosynergistic antileukemic effects on AML when VPA is used in combination with other chemotherapy agents including idarubicin, 21 5-aza-2'-deoxycytidine, 22 gemtuzumab ozogamicin, 23 and NPI-0052. 24 Recently, VPA was reported to markedly increase cytarabine cytotoxicity in a single AML cell line. 25 However, neither the mechanisms of interaction between VPA and cytarabine nor the extent to which these results can be generalized to different AML subtypes have been established.
In this study, we hypothesize that VPA synergizes with cytarabine, resulting in enhanced antileukemic activity in AML cells, by inducing apoptosis. To model this concept, we examined the impact of VPA on cytarabine cytotoxicities in 4 pediatric AML cell lines and 9 diagnostic blast samples from children with de novo AML. We demonstrate highly synergistic antileukemic activities of combined cytarabine and VPA in all of the cell lines and diagnostic blast samples, especially those with t(8;21). Our mechanistic studies reveal cooperative induction of DNA damage by cytarabine and VPA and induction of Bim by VPA that underlie the synergistic activity of this drug combination. Collectively, our results provide compelling evidence to
In Vitro Cytotoxicity Assays
In vitro cytarabine and VPA cytotoxicities of pediatric AML cell lines and diagnostic blasts were measured by using MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazoliumbromide, Sigma) assays, as previously described. 26 IC 50 values were calculated as drug concentrations necessary to inhibit 50% proliferation compared to untreated control cells. The extent and direction of cytarabine and VPA cytotoxic interactions were evaluated as described previously. 27, 28 Briefly, synergism, additivity or antagonism was quantified by determining the combination index (CI), where CI<1, CI=1, and CI>1 indicate synergistic, additive, and antagonistic effects, respectively. Based on the classic isobologram, the CI was calculated using 
Assessment of Baseline and Drug Induced Apoptosis
Diagnostic AML blasts from patient 7 [46, XY, t(8;21)], THP-1, and Kasumi-1 cells cultured in RPMI1640 plus 10-20% FBS were treated with VPA (0.5, 0.66, and 0.5 mM, respectively) or cytarabine (1000, 900, and 100 nM, respectively) alone or in combination for 24 h (for the patient sample) or 96 h (for the cell lines). The VPA and cytarabine doses for the cell lines were IC 20 s, while those for patient AML blasts were ~IC 50 s, determined by MTT assays.
The same concentrations of VPA and cytarabine were used in the rest of the studies unless specified. The cells were harvested, vigorously pipetted and triplicate samples taken to determine baseline and drug-induced apoptosis using the Apoptosis Annexin-V fluorescein isothiocyanate (FITC)/propidium iodide (PI) Kit (Beckman Coulter; Brea, CA), as previously described. 
Western Blot Analysis
Extracted or immunoprecipitated proteins were subjected to SDS-polyacrylamide gel electrophoresis. Separated proteins were electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes (Thermo Fisher Inc., Rockford, IL) and immunoblotted with antiacetyl-histone 3 (ac-H3), -ac-H4, -H4 (Upstate Biotechnology, Lake Placid, NY), -Bak, -Bax, -Bid, -Bim, -Bad, -Puma, -p21, -Bcl-2, -Bcl-xL, -Mcl-1, -γH2AX (Cell Signaling Technology, Danvers, MA), or -β-actin (Sigma, St Louis, MO) antibody, as described previously. 
RESULTS

Synergistic Antileukemic Interactions between Cytarabine and VPA in Pediatric AML Cell
Lines and Diagnostic Blasts
To explore the possibility of synergistic cytotoxicity when cytarabine was combined with HDACIs to treat pediatric AMLs, we tested VPA [a short-chain fatty acid HDACI which inhibits class I and class IIa HDACs Figure 1D ) and by calculating CI values. 28 A CI<1, indicative of synergism, was calculated for each of the drug combinations (Table 1) .
To determine whether the synergistic antileukemic activity of VPA and cytarabine was unique to the THP-1 subline, analogous cytotoxicity experiments were performed with the Kasumi-1, MV4-11, and CMS sublines derived from children with different AML subtypes.
VPA showed variable cytotoxicities in the 3 additional AML sublines, with IC 50 s ranging from 0.37 to 2.7 mM (Table 1) . It is interesting that MV4-11 [harbors t(4;11)] and Kasumi-1 [harbors t(8;21)] cells were both substantially more sensitive to VPA than were the THP-1 and CMS sublines ( Table 1) Table 1) . The results with the MV4-11 cells are particularly interesting since they harbor a FLT3 ITD in addition to t(4;11). 31 For CMS cells, simultaneous administration of VPA and cytarabine also resulted in 2-fold decreased cytarabine IC 50 at 1 mM VPA, compared to that from cytarabine alone ( Table 1) .
Analogous results were obtained when AML blasts collected at diagnosis from 9 children with de novo AML were evaluated following co-treatment with cytarabine and VPA (0.15 to 1 mM) ( Table 1) . As with Kasumi-1 cells, diagnostic blasts from t(8;21) AML cases (n=3, patients 7-9) were significantly more sensitive to VPA than non-t(8;21) AML blasts (n=6, patients 1-6) (median VPA IC 50 0.38 mM vs 1.41 mM, p=0.024, Table 2 and Figure 1E ) and showed 6.5-to 64.1-fold decreased cytarabine IC 50 s when combined with VPA at doses 0.5 mM or lower, compared to that from cytarabine alone. By contrast, non-t(8;21) AML blasts only showed 1.3-to 13-fold decrease in cytarabine IC 50 s when combined with 0.5 mM VPA (p=0.024, Table 2 and Figure 1F ).
For both AML cell lines and diagnostic blast samples, cytarabine and VPA were again synergistic by isobologram analyses (not shown) and by CI values (Table 1) . Collectively, our results demonstrate that synergistic antileukemic effects of combined cytarabine and VPA are broad-ranging and occur in multiple AML subtypes.
VPA and Cytarabine Synergistically Induce Apoptosis of Pediatric AML Cells
We hypothesized that VPA may lower the apoptotic threshold in pediatric AML cells, rendering them more susceptible to apoptosis induced by cytarabine. Another possibility could be that VPA combines with cytarabine to induce cell cycle arrest, resulting in synergistic antileukemic activity on this basis. To test these hypotheses, THP-1 and Kasumi-1 cells, treated Figures 2C and 2D ). These results demonstrate that VPA augments both apoptosis and S phase arrest induced by cytarabine in THP-1 and Kasumi-1 cells.
To extend these latter results to diagnostic AML patient samples, blasts from patient 7 (Table 1) for which there were sufficient cells were treated with cytarabine and VPA individually or in combination for 24 h and analyzed by flow cytometry for apoptosis and cell cycle distribution. Again, there was a synergistic induction of apoptosis by combined cytarabine and VPA (cooperativity index = 0.82, Figure 2E ). Changes in cell cycle distribution in the blasts could not be determined due to lack of cell proliferation (not shown).
Research. h were subjected to caspase-9 and caspase-3 enzymatic assays. In Figure 3 , co-treatments with cytarabine and VPA resulted in synergistic activation of caspases 9 and 3 in both cell lines.
These results demonstrate that cytarabine and VPA synergistically induce apoptosis of pediatric AML cells through the intrinsic apoptotic pathway.
VPA and Cytarabine Cooperatively Induce DNA Damage in THP-1 and Kasumi-1 Cells
Efforts were then undertaken to determine the molecular mechanisms that underlie the synergistic induction of apoptosis by the two agents. Cytarabine is a DNA damaging agent which causes DNA double strand breaks. A previous study suggested that HDACIs can also cause DNA damage in leukemia cells. 9 Thus, we hypothesized that cytarabine and VPA cooperate in causing DNA damage, which subsequently triggers apoptosis. To test this possibility, THP-1 and Kasumi-1 cells were treated with variable concentrations of cytarabine or VPA, alone or combined for 96 h, and protein lysates were subjected to Western blotting to detect γH2AX, a biomarker of DNA double strand breaks. 32 Interestingly, co-treatment with VPA and cytarabine resulted in distinctly cooperative induction of γH2AX in both cell lines ( Figure 4A ). In Kasumi-1 cells, this cooperative induction of γH2AX was both cytarabine and VPA concentration dependent ( Figure 4B ). These results establish that VPA augments cytarabine-induced DNA double strand breaks which may trigger apoptosis. It is important to note that there was no difference in the extent of synergy of VPA (0.5 mM) with 100 or 200 nM cytarabine in terms of triggering DNA damage. This suggests that combing the two agents would allow for a dose reduction in cytarabine.
Research. 
Induction of γH2AX by combined VPA/cytarabine was an early molecular event in
Kasumi-1 cells, as revealed by a time course study ( Figure 4C ). Thus, substantial induction of γH2AX (2.6-fold increase relative to control) was detected by Western blotting as early as at 1.5 h (Figure 4C ), accompanied by caspase-3 activation starting at 6 h ( Figure 4D) . Further, the levels of γH2AX significantly correlated with caspase-3 activities over 48 h (r = 0.90, p = 006, Figure 4E ). However, this association was abolished when the 96 h time data were included (r = 0.68, p = 0.06, Figure 4F ). These results strongly suggest that DNA damage was associated with caspase-3 activation in Kasumi-1 cells treated with combined cytarabine and VPA during early times (within 48 h). There may be other factor(s) contributing to the late time (96 h) caspase-3 activation in this experiment.
Bim is a Critical Determinant of Apoptosis Induced by Cytarabine and Combined VPA and Cytarabine in Pediatric AML Cells
Previous studies showed that HDACIs can induce Bim to promote apoptosis in cancer cells. 33, 34 It is conceivable that VPA also induces Bim expression in pediatric AML cells, thus contributing to apoptosis induced by combined VPA and cytarabine. As shown in Figures 5A and 5B, modest induction of the BimEL isoform by VPA and VPA plus cytarabine was detected in both THP-1 and Kasumi-1 cells. In contrast, levels for other Bcl-2 family proteins were largely unchanged (Supplementary Figure S1) . These results suggest that Bim could be another important determinant for the antileukemic activities of combined VPA/cytarabine in pediatric AML cells. In contrast to the DNA damage response, induction of Bim appeared to be a later molecular event in both sublines (post 48 h treatment, Figure 5C ). This could explain the disproportionately increased caspase-3 activation seen at later times in Kasumi-1 cells (48 h and 96 h, Figure 4D ). 
DISCUSSION
HDAC inhibition represents one of the most promising epigenetic treatments for cancer because HDACIs have been established to reactivate silenced genes and exert pleiotropic antitumor effects selectively in cancer cells. 5 The ability of HDACIs to induce cell differentiation, cell cycle arrest, and apoptosis in human leukemic cells but not in normal cells has stimulated significant interest in clinical applications as anti-leukemic agents. 5, [18] [19] [20] Currently, HDACIs including the anti-epileptic agent VPA are being evaluated in the treatment of acute leukemias. [13] [14] [15] Despite their well-characterized molecular and cellular effects, single-agent activity of this class of drugs has been modest. 5 Accordingly, there has been significant interest in developing rationally designed combination therapies using HDACIs.
In this study, we analyzed the cellular and molecular effects of combined cytarabine and VPA in a panel of clinically relevant pediatric AML cell lines and diagnostic blasts from children with de novo AML. Our rationale was based on the central role of cytarabine in AML chemotherapy [1] [2] [3] and on the documented ability of VPA to induce apoptosis specifically in leukemia cells, without causing proliferation inhibition of normal hematopoietic progenitor cells 35 . Indeed, phase I/II studies using VPA as a single agent for adults with refractory AML or myelodysplastic syndrome have shown that VPA is well tolerated. 15, 36 The activity of VPA alone or in combination with cytarabine was initially evaluated against THP-1 AML cells, the most cytarabine resistant subline tested in our study. showed the greatest response to co-treatment with cytarabine and VPA. This was not unexpected, given that several fusion proteins (AML-1/ETO, PML-RARA, etc) recruit nuclear co-repressor complexes (which contain HDACs) 7 . Thus AML cases harboring these fusion genes might be preferentially susceptible to HDACIs. Previous pharmacokinetic studies have shown that clinically achievable trough levels of VPA used in the treatment of children with epilepsy 37 approximate the in vitro concentrations of VPA that synergized with cytarabine in our study.
The synergistic cytotoxicity of combined cytarabine and VPA is clearly due to cell death since synergistic induction of apoptosis by the two agents in both pediatric AML cell lines and diagnostic blasts was detected. In THP-1 cells, VPA inhibited cell cycle progression at G1/S, which may block apoptosis mediated by the HDACI. 
elusive. Additional studies are underway to further determine the effects of HDACIs in inducing DNA damage in this disease.
Besides induction of DNA damage, both VPA and combined VPA/cytarabine also induced expression of the BH3-only pro-apoptotic protein, Bim, in both Kasmui-1 and THP-1 cells. Bim has been classified as an "activator" in view of its purported ability to engage directly and activate Bax and Bak. 39 It has been well documented that Bim is critical for HDACI-induced apoptosis of both solid tumor and leukemia cells. 33, 34 In this study, we demonstrated that Bim also plays critical roles in cytarabine and cytarabine plus VPA induced apoptosis in pediatric AML cells. However, Bim may not be responsible for the synergy between the two agents since only VPA, but not cytarabine, induced Bim expression in our experiments. 
